Low-Grade Stage III-IV Follicular Lymphoma: Multivariate Analysis of Prognostic Factors in 484 Patients—A Study of the Groupe d'Etude des Lymphomes de l'Adulte
- 1 August 1999
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (8), 2499
- https://doi.org/10.1200/jco.1999.17.8.2499
Abstract
PURPOSE: To identify the prognostic factors that influence overall survival (OS) in patients with stage III-IV follicular lymphomas and evaluate the clinical usefulness and the prognostic value of the International Prognostic Index (IPI). PATIENTS AND METHODS: Four hundred eighty-four patients with Ann Arbor stage III-IV follicular lymphomas treated in two phase III trials from 1986 to 1995 were screened for this study. All histologic slides were reviewed by two hematopathologists. The influence of the initial parameters on survival was defined by univariate (log-rank test) and multivariate (Cox model) analyses. RESULTS: The poor prognostic factors for OS (age > 60 years, “B” symptom(s), ≥ two extranodal sites, stage IV disease, tumor bulk > 7 cm, at least three nodal sites > 3 cm, liver involvement, serous effusion-compression or orbital/epidural involvement, and erythrocyte sedimentation rate > 30 mm/h) that were significant in univariate analysis were subjected to multivariate analysis. Three factors remained significant: B symptom(s) (risk ratio = 1.80), age greater than 60 years (risk ratio = 1.60), and at least three nodal sites greater than 3 cm (risk ratio = 1.71). When the IPI was applied to these patients, the score was 1, 2, 3, and 4-5 in 49%, 39%, 11%, and 2%, respectively, and it was significant for progression-free survival (P = .002) and OS (P = .0001). CONCLUSION: Three prognostic factors for poor OS were identified: B symptoms, age greater than 60 years, and at least three nodal sites greater than 3 cm. The IPI was prognostic for OS, but in this population, a very low number of patients belonged to the high-risk groups.Keywords
This publication has 20 references indexed in Scilit:
- Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.Journal of Clinical Oncology, 1998
- IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1997
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Identification of Prognostic Groups in Follicular LymphomaLeukemia & Lymphoma, 1993
- Low-grade follicular lymphomas: Analysis of prognosis in a series of 281 patientsEuropean Journal of Cancer and Clinical Oncology, 1991
- The identification of discrete prognostic groups in low grade non-Hodgkin's lymphomaAnnals of Oncology, 1991
- Prognostic Value of Serum β-2 Microglobulin in Low-Grade LymphomaAnnals of Internal Medicine, 1991
- Follicular lymphomas: Assessment of prognostic factors in 127 patients followed for 10 yearsAnnals Of Oncology, 1991
- Treatment of low-grade non-Hodgkin's lymphomas: Assessment of doxorubicin in a controlled trialHematological Oncology, 1990
- Prognostic factors in nodular lymphomas: A multivariate analysis based on the Princess Margaret Hospital experienceInternational Journal of Radiation Oncology*Biology*Physics, 1984